Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00398411 · OUTCOME

Type of Isolates and Infections

Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells · Source last updated 2015-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)

Analysis population: intention to treat (ITT)

Groups in this outcome

Moxifloxacin

moxifloxacin 400 mg tablets once daily

Placebo

identical appearing placebo

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Moxifloxacin34
Placebo32

Reported measurements

bacteremia isolate: enterococcus faecalis
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin0Not reportedNot reportedNot reportedNot reported
Placebo2Not reportedNot reportedNot reportedNot reported
bacteremia isolate: escherichia coli
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin1Not reportedNot reportedNot reportedNot reported
Placebo3Not reportedNot reportedNot reportedNot reported
bacteremia isolate: klebsiella pneumoniae
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin0Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
bacteremia isolate: pseudomonas aeruginosa
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin1Not reportedNot reportedNot reportedNot reported
Placebo0Not reportedNot reportedNot reportedNot reported
bacteremia isolate: staphylococcus aureus
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin1Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
bacteremia isolate: staphylococcus epidermidis
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin0Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
bacteremia isolate: streptococcus species
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin0Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
clostridium difficile infection
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin1Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
mucositis
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Moxifloxacin0Not reportedNot reportedNot reportedNot reported
Placebo1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        2
    title
    bacteremia isolate: enterococcus faecalis
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        3
    title
    bacteremia isolate: escherichia coli
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
    title
    bacteremia isolate: klebsiella pneumoniae
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
    title
    bacteremia isolate: pseudomonas aeruginosa
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
    title
    bacteremia isolate: staphylococcus aureus
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
    title
    bacteremia isolate: staphylococcus epidermidis
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
    title
    bacteremia isolate: streptococcus species
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
    title
    clostridium difficile infection
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
    title
    mucositis
denoms
  1. counts
    1. group Id
      OG000
      value
      34
    2. group Id
      OG001
      value
      32
    units
    Participants
groups
  1. description
    moxifloxacin 400 mg tablets once daily
    id
    OG000
    title
    Moxifloxacin
  2. description
    identical appearing placebo
    id
    OG001
    title
    Placebo
param Type
NUMBER
population Description
intention to treat (ITT)
reporting Status
POSTED
time Frame
end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)
title
Type of Isolates and Infections
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice